Biogen Inc. (BIIB)
|52 Week Range||188.54-319.74|
|1y Target Est||-|
|DCF Unlevered||BIIB DCF ->|
|DCF Levered||BIIB LDCF ->|
|Debt / Equity||-|
Upgrades & Downgrades
Latest BIIB news
Mastering the Double-Bottom Pattern (Unveiling 3 Intriguing Setups in Today's Market)
7 June 2023
A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils ...
Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
6 June 2023
Biogen BIIB announced that it is discontinuing one of the two studies on its and partner Denali Therapeutics' DNLI small molecule LRRK2 inhibitor, BIIB122, for Parkinson's disease.
Medicare unveils plan for coverage of new Alzheimer's drugs
1 June 2023
Medicare on Thursday announced plans for coverage of new Alzheimer's drugs whose accessibility has become a point of controversy.
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
1 June 2023
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.
Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?
25 May 2023
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
19 May 2023
The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our...
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
19 May 2023
Biogen and Eli Lilly both have promising Alzheimer's drugs that have shown they are effective in slowing the rate of cognitive decline in patients. They both come with risks related to brain swelling ...
Jim Cramer expects defensive stocks to be resilient as debt ceiling talks drag on
15 May 2023
CNBC's Jim Cramer is looking to 2011 for investing guidance during the ongoing debt ceiling uncertainty.
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
14 May 2023
Two new medicines are going to compete for the Alzheimer's therapy market. Eli Lilly's candidate appears to be more effective, but it isn't approved yet.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >